Will the FDA approve gedatolisib for advanced breast cancer?
gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancerScience
Will the FDA approve gedatolisib for advanced breast cancer?
gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancerScience
Kalshi 活跃 5 个市场·81¢ Will the FDA approve gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer before Jul 1, 2027?·$0 总交易量·-- 流动性·-- OI
22d 17h·Jul 8, 2026
追踪你的预测市场持仓
连接你的 Kalshi 账户，追踪你的合约、盈亏和结算。
较大价差
暂无图表数据
市场
5HR+/HER2-, PIK3CA wild-type before Jul 2027
$0 vol
HR+/HER2-, PIK3CA wild-type before Jan 2027
$0 vol
HR+/HER2-, PIK3CA wild-type before Aug 2026
$0 vol
HR+/HER2-, PIK3CA wild-type before Oct 2026
$0 vol
HR+/HER2-, PIK3CA wild-type before Jul 2026
$0 vol
HR+/HER2-, PIK3CA wild-type before Jul 2027
暂无订单簿数据
If the FDA approves gedatolisib for HR+/HER2-, PIK3CA wild-type advanced breast cancer for marketing before Jul 1, 2026, then the market resolves to Yes.
追踪您在 Kalshi 上的投注——以及一切其他资产
从您的 Kalshi 头寸、盈亏和实时赔率开始，创建免费投资组合。然后添加加密钱包、交易所、DeFi 等——一切尽在一处。
Polymarket
Kalshi
50+ Chains
40+ Exchanges
DeFi
NFTs
16K+ Tokens
100% 免费· 只读· 加密保护